Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.57 |
| ▸ | MMP3 | P08254 | 7/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 6/20 | 0.56 |
| ▸ | MMP2 | P08253 | 6/20 | 0.56 |
| ▸ | MMP8 | P22894 | 4/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715141 | 0.92 | EPHX2 (0.63) | EPHX1MMP3MMP1MMP2EPHX2 | |
| SCHEMBL5520607 | 0.88 | CTSK (0.55) | EPHX1MMP3CNR1MMP1MMP2 | |
| SCHEMBL5520650 | 0.84 | RAB9A (0.61) | EPHX1CNR1MMP1MMP8EPHX2 | |
| SCHEMBL7355387 | 0.83 | METAP2 (0.62) | EPHX1MMP3CNR1MMP1MMP2 | |
| Hydrochloric Acid SCHEMBL7354348 | 0.82 | METAP2 (0.61) | EPHX1MMP3CNR1MMP1MMP2 | |
| SCHEMBL5528697 | 0.81 | CTSK (0.57) | EPHX1MMP3MMP1MMP2EPHX2 | |
| SCHEMBL4715413 | 0.80 | MMP3 (0.54) | MMP3MMP1MMP2EPHX2 | |
| SCHEMBL12932019 | 0.79 | EPHX2 (0.84) | EPHX1EPHX2KMT2A | |
| SCHEMBL5526987 | 0.78 | SMN1; SMN2 (0.53) | MMP3EPHX2KMT2ACYP2C9 | |
| SCHEMBL7358712 | 0.78 | EPHX2 (0.61) | EPHX1MMP3MMP1MMP2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1399146-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARM INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1399146-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | EPHX1 2078/4885MMP3 88/4885CNR1 1771/4885 |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | CAPNS1, CTSS, CTSV | EPHX1 4489/4885MMP3 34/4885CNR1 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.